Farrukh Awan, MD
Latest in Blood Cancer Treatment
Dr. Farrukh Awan is an associate professor and hematologist-oncologist at UT Southwestern, who specializes in treating people diagnosed with leukemia and lymphoma.
Explore below for his insights on everything from what blood cancers are, the landscape of current and upcoming treatments, clinical trials, new targeted therapies (including a venetoclax-selinexor Phase 1 trial), emerging T-cell therapies for blood cancers like bispecifics and CAR T, and the importance of patient access to these new treatments.
Dr. Awan is also a member of several professional organizations, including the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH). He is also the recipient of the Young Investigator Award from ASCO and has published on many topics, including ibrutinib and acalabrutinib.
Dr. Awan’s Insights
Blood Cancer Treatment
Dr. Awan shares his work background on leukemia and lymphoma, and the overall picture of progress in blood cancer treatment.
Clinical Trials
Explore how to approach learning about what clinical trials might be the best options and how to discuss them with your doctor.
Venetoclax-Selinexor Trial
Dr. Awan shares about one clinical trial (phase 1) he’s a part of in exploring more treatment options for relapsed/refractory lymphoma patients – venetoclax-selinexor.
Bispecific T-Cell Engager
Dr. Awan describes bispecific T-cell engagers (bispecifics), an emerging T-cell therapy that’s being investigated for the treatment of blood cancers
CAR T-Cell Therapy
Learn more about CAR T-cell therapy, an ever-emerging treatment option for some people diagnosed with relapsed/refractory non-Hodgkin lymphoma.
Patient Access to Treatments
Dr. Awan says there’s still a major issue with lack of access to new and upcoming treatments and resources for many patients.
Thank you so much, Dr. Awan!
More from Hematologist-Oncologists
Advances in GVHD Treatments and Clinical Trials
Hematologist-oncologists Dr. Satyajit Kosuri and Dr. Shernan Holtan, patient advocate Meredith Cowden, and LLS clinical trial nurse navigator Ashley Giacobbi discuss the role clinical trials play in advancing the GVHD treatment landscape.
...
Accessing the Best Care for You or a Loved One: Understanding New Options for Non-Hodgkin Lymphoma
Dr. Kulsum Bano, Dr. Nilanjan Ghosh, and Dr. Justin Favaro discuss the latest advances with 3-time DLBCL survivor and patient advocate Dr. Robyn Stacy-Humphries.
...
Rafael Fonseca, MD
Role: Interim executive director, hematologist-oncologist
Focus: Multiple myeloma, new drug development
Institution: Mayo Clinic
...
Farrukh Awan, MD
Role:Hematologist-oncologist, associate professor
Focus:Leukemias, Lymphomas, BMT
Institution:UT Southwestern
...
Nina Shah, MD
Role: Hematologist-oncologist, researcher
Focus: Multiple Myeloma
Institution: University of California, San Francisco (UCSF)
...
Kerry Rogers, MD
Role: Hematologist, researcher
Focus: Chronic lymphocytic leukemia (CLL), Hairy Cell Leukemia (HCL)
Institution: OSUCCC-The James
...
Tim Fenske, MD, MS
Role: Hematologist-Oncologist
Focus: chronic lymphocytic leukemia (CLL) & leukemia and lymphoma | CAR T, targeted therapy
Provider: Medical College of Wisconsin
...
Irene Ghobrial, MD
Role: Clinical investigator and professor of hematological oncology
Focus: Multiple myeloma, Waldenström’s Macroglobulinemia, early screening, clinical trials
Provider:Dana-Farber Cancer Institute (Boston)
...
Edmund Tai, M.D.
Role: General oncologist, hematologist
Focus: Specialist in treating Chinese-speaking patients
Provider: Sutter Health (Bay Area, CA)
...
Jacqueline Barrientos, MD
Role: Hematologist, researcher
Focus: Chronic lymphocytic leukemia (CLL), lymphoma, 17p Deletion (Ibrutinib, Acalabrutinib, Venetoclax), IgHV mutation
Provider: Northwell Health (NYC)
...
James Berenson, MD
Oncologist: Specializing in myeloma and other blood and bone disorders
Experience: 35+ years
Institution: Berenson Cancer Center
...